CytoSorbents (STU:HQE) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:HQE CytoSorbents Corp STU:HQE
45 GF Score
Price €5.92
GF Value €16.19
! 5 Warning Signs
View Full Analysis

What is CytoSorbents Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:HQE
45GF Score
CytoSorbents Corp STU:HQE
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CytoSorbents (STU:HQE) Overvalued in 2026?

Based on GuruFocus' analysis, CytoSorbents stock appears to be undervalued. The current stock price of €5.92 is trading 63.4% below its estimated GF Value™ of €16.19.

Key valuation signals for STU:HQE:

  • Short Ratio:
  • GF Value™: €16.19 vs. price of €5.92 (63.4% below fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the STU:HQE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CytoSorbents Business Description

Other Exchanges CTSO:USA
Address 305 College Road East, Princeton, NJ, USA, 08540
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
45GF Score

Get the complete analysis for STU:HQE

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.92
Price
€16.19
GF Value